Abstract

Objective To study the drug chemotherapy of CP in combination with thalidomide(Thd) in treatment of advanced ovarian carcinoma. Methods From July 2004 to December 2007, 26 cases with advanced ovarian carcinoma was randomly divided into two groups. Group A(n=13) were treated with cyclophosphamide [CTX, (500~700) mg/m2]+ diamminedichloroplatinum [DDP, (50~75) mg/m2]+ thalidomide (200 mg/d), and group B were treated with cyclophosphamide[(500~700) mg/m2]+ diamminedichloroplatium [(50~75) mg/m2]. Informed consent was obtained from all participants. Vascular endothelial growth factor (VEGF), tumor necrosis factor (TNF)-α, and cancer antigen (CA)125 level in serum were determined by enzyme-linked inmunonosorbent assay(ELISA) in two groups. Results The level of vascular endothelial growth factor, cancer antigen125 in group B were significantly lower than those of group A, and the level of tumor necrosis factor-α of group B was significant lower than that of group A after treatment(P<0.01, P<0.05). Conclusion Thalidomide might prove the antitumor drug therapy on advanced ovarian carcinoma. Key words: thalidomide; advanced ovarian carcinoma; drug therapy

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.